A company of theRHÖN-KLINIKUM AG
Deutsch
A A A
DE
A A A
Deutsch
Philipps Universität Marburg Philipps Universität Marburg Fachbereich 20 – Medizin
Justus-Liebig-Universität Gießen Justus-Liebig-Universität Gießen Fachbereich 11 – Medizin
Bereichsnavigation

Previous
RHÖN-KLINIKUM AG | 02/27/2015

RHÖN-KLINIKUM AG: Provisional Figures for Financial Year 2014

  • Roughly 1.22 million patients treated
  • Financial figures significantly affected by special influences due to sales transaction
  • Revenues amount to EURO 1.51 billion
  • EBITDA stands at EURO 1.41 billion due to sales transaction
  • Net consolidated profit amounts to EURO 1.23 billion
  • Outlook for 2015: revenues between EURO 1.08 billion and EURO 1.12 billion, EBITDA between EURO 145 million and EURO 155 million

The sale of a total of 43 hospitals which was completed in financial year 2014 significantly influenced the business of RHÖN-KLINIKUM AG in the past year. It is difficult to make a direct comparison of the financial figures with previous years – in particular with 2013 – due to one-off effects which can generally be attributed to the transaction as well as the fact that the hospital portfolio was being restructured. The financial statement for the first two months of 2014 was drawn up with the full consolidation of the previous portfolio in its entirety while the portfolio was gradually reduced with the operational transfer of the hospitals from March onwards so that the corporate group consisted of ten hospitals in five locations at the end of the year.

Against this background roughly 1.22 million patients were treated in our hospitals in 2014. Corporate revenues stood at EURO 1.51 billion with earnings before interest, taxes, depreciation and amortisation (EBITDA)amounting to EURO 1.41 billion due to the proceeds from the sale of the hospitals and net consolidated profit was at EURO 1.23 billion.

“The far-reaching changes in our corporate structure and the strategic re-orientation of our corporate group do not simply follow a normal daily business routine. The financial figures are generally very satisfying against the background of the continually demanding specific framework conditions in the strongly regulated competitive environment of the healthcare market,” Dr. Dr. Martin Siebert, CEO of RHÖN-KLINIKUM AG, stated. “The long-term emphasis on treatment excellence and high quality as well as on the consistent and continuous expansion of network medicine will both contribute in the medium term to our company developing in a dynamic manner. We shall continue to argue with emphasis for appropriate remuneration of our cutting-edge medical care in all our hospitals.”

Jens-Peter Neumann, CFO of RHÖN-KLINIKUM AG, added: “We have a solid financial basis for the future following completion of the sales transaction. Our strong financial structure is a precondition for organic growth in the future by means of medical innovation as well as growth through acquisitions, if appropriate. Following the sales transaction we can now concentrate all our strength on the corporate re-orientation.”

Outlook

The company expects revenues of EURO 1.08 billion to EURO 1.12 billion and earnings before interest, taxes, depreciation and amortisation (EBITDA) of between EURO 145 million and EURO 155 million for the current financial year 2015, the first full financial year with the new portfolio structure. As in 2013 and 2014, one-off effects will continue to influence the corporate results during this financial year as well, although to a lesser degree than in the past two years. The size of these positive and negative special influences is a low two-digit million figure; they will be priced in gradually over the entire financial year 2015 and will partially cancel each other out during the year. Regulatory changes, progress in major legal matters and financial effects from handling the transaction with Fresenius/Helios must also be taken into account here.

Dr. Dr. Martin Siebert continued: “RHÖN-KLINIKUM AG has come into its own with its new structure. We are now able to work more efficiently by exchanging synergy effects on a stronger basis and using expertise and experience across different sites to an even greater degree. Our patients continue to remain the focal point of our corporate re-orientation. Innovation and treatment excellence in our hospitals providing maximum medical care allow us to provide our patients, who are often seriously ill, with high-class medical and nursing care.”